Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

• Market Cap: ₹26.38B
• Dividend Yield: N/A
• Average Volume (3M): 16.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: -0.01%
• EPS Growth: -616.18%
• Country: IN
• Employees: 1,936
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.31
• Shares Outstanding: 61,250,744
• 10 Day Avg. Volume: 16,857
• 30 Day Avg. Volume: 16,745
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹424.00
• Price Target Upside: 8.16% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: ₹424.00 ▲(8.16% Upside)

Panacea Biotec's overall stock score reflects significant financial and valuation challenges. The company's struggles with profitability and cash flow are major concerns, compounded by a negative P/E ratio. Technical indicators provide a mixed outlook, with no strong bullish or bearish signals. The absence of earnings call data and corporate events limits additional insights.

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Panacea Biotec Limited (PANACEABIO) is a leading biotechnology and pharmaceutical company based in India, focusing on the development, manufacturing, and marketing of vaccines, pharmaceuticals, and biosimilars. The company's core products include vaccines for infectious diseases, immunosuppressants, and critical care medicines, catering to both domestic and international markets.

How the Company Makes Money

Panacea Biotec generates revenue through the sale of its pharmaceutical products and vaccines, which are distributed in both domestic and international markets. The company's primary revenue streams include the manufacturing and sale of vaccines for diseases such as polio and tetanus, as well as pharmaceuticals used in therapies for organ transplantation, oncology, and diabetes management. Panacea Biotec also engages in partnerships and collaborations with global pharmaceutical companies to develop and commercialize various drug products. These strategic alliances and licensing agreements further contribute to its earnings, alongside government contracts and supply agreements for vaccines.

Panacea Biotec Limited Financial Statement Overview

Summary

Panacea Biotec faces significant financial challenges, with declining revenue, negative profitability, and liquidity issues. Despite a strong equity position, the stagnant revenue and consistent net losses indicate operational difficulties, impacting the financial performance score adversely.

Income Statement

Panacea Biotec's income statement shows mixed performance with declining revenue and profitability. The gross profit margin for 2025 is approximately 64.31%, indicating decent cost management. However, the company has been experiencing negative EBIT and net income, reflecting operational challenges. The net profit margin is negative due to consistent net losses, and revenue growth has stagnated, showing no growth from 2024 to 2025.

Balance Sheet

The balance sheet indicates a strong equity position with a debt-to-equity ratio of 0.03 in 2025, showing effective leverage management. However, the company has faced declining total assets and stockholders' equity over the years. The equity ratio stands at 64.73% in 2025, suggesting a stable financial structure, but the decline in assets could be a concern for future growth.

Cash Flow

Panacea Biotec's cash flow statement reveals liquidity challenges, with negative operating cash flow and free cash flow in 2025. The company is struggling to generate cash from operations, reflected in the negative operating cash flow to net income ratio. The free cash flow to net income ratio is also negative, indicating a need for improvement in cash generation.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	5.59B	5.59B	4.60B	6.59B	6.18B
Gross Profit	3.60B	3.29B	2.07B	3.42B	4.13B
EBITDA	307.40M	415.37M	563.65M	16.74B	865.18M
Net Income	-83.70M	-11.73M	-332.37M	10.78B	-1.48B
Balance Sheet
Total Assets	12.90B	12.41B	12.71B	17.59B	11.78B
Cash, Cash Equivalents and Short-Term Investments	1.79B	1.56B	2.13B	5.52B	954.44M
Total Debt	222.10M	209.90M	202.19M	341.55M	8.20B
Total Liabilities	4.59B	4.02B	4.31B	8.85B	14.09B
Stockholders Equity	8.35B	8.42B	8.44B	8.77B	-2.29B
Cash Flow
Free Cash Flow	-776.80M	-778.18M	-4.63B	-1.21B	850.01M
Operating Cash Flow	-273.70M	-1.00M	-4.22B	-1.08B	1.07B
Investing Cash Flow	649.80M	102.27M	4.30B	12.83B	-476.79M
Financing Cash Flow	-26.60M	-28.08M	-183.73M	-11.76B	-471.10M

Panacea Biotec Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 392.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Negative. The current price of 392 is below the 20-day moving average (MA) of 417.87, below the 50-day MA of 425.62, and below the 200-day MA of 424.43, indicating a bearish trend. The MACD of -7.51 indicates Positive momentum. The RSI at 40.17 is Neutral, neither overbought nor oversold. The STOCH value of 35.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKEM	72 Outperform	₹615.84B	26.96		0.83%	4.49%	11.22%
AUROPHARMA	71 Outperform	₹614.49B	18.12		0.38%	7.76%	-2.83%
IPCALAB	66 Neutral	₹349.17B	44.84		0.29%	11.49%	35.00%
GLAXO	65 Neutral	₹438.60B	46.16		2.01%	6.65%	48.47%
GLENMARK	62 Neutral	₹580.50B	55.43		0.12%	9.39%	―
Sector *	51 Neutral	$7.42B	-0.36	-40.86%	2.27%	22.89%	-2.16%
PANACEABIO	47 Neutral	₹26.38B	―		―	-0.01%	-616.18%